Fig. 1From: FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extensionPatient disposition in Periods I and II (encompassing the double-blind and extension study). AE adverse event, DB double-blind, OLE open-label extension, RP reference product. *Including two patients treated with FKB327 and one patient treated with RP who discontinued study treatment due to lack of efficacyBack to article page